Healthy controls (N = 19) | Patients with persistent symptoms following treated Lyme disease (N = 12) | P a | |
---|---|---|---|
Age, years | 51.0 [38.5, 56.0] (22.0, 62.0) | 42.0 [39.5, 47.3] (24.0, 63.0) | 0.361 |
Sex, male | 13 (68.4%) | 5 (41.7%) | 0.262 |
Race | 0.002 | ||
White | 8 (42.1%) | 12 (100.0%) | |
Black | 10 (52.6%) | 0 (0.0%) | |
Mixed | 1 (5.3%) | 0 (0.0%) | |
Body mass index | 27.7 ± 4.1 (20.6, 34.0) | 25.8 ± 3.8 (20.8, 33.2) | 0.193 |
Genotype, C/T | 6 (31.6%) | 8 (66.7%) | 0.075 |
Injected dose (MBq) | 692.3 ± 20.4 | 691.4 ± 15.3 | 0.886 |
Injected mass (μg) | 1.0 ± 0.4 | 1.0 ± 0.5 | 0.839 |
Specific activity (GBq/μmol) | 293.6 ± 177.8 | 310.4 ± 101.1 | 0.741 |
Regional volume ratiob | |||
Cerebellum | 0.063 ± 0.009 (0.049, 0.080) | 0.073 ± 0.005 (0.065, 0.081) | < 0.001 |
Hippocampus | 0.006 ± 0.001 (0.005, 0.007) | 0.006 ± 0.000 (0.005, 0.006) | 0.363 |
Occipital Cortex | 0.030 ± 0.003 (0.025, 0.037) | 0.028 ± 0.004 (0.017, 0.033) | 0.072 |
Frontal cortex | 0.111 [0.107, 0.114] (0.085, 0.125) | 0.111 [0.109, 0.114] (0.058, 0.122) | 0.984 |
Parietal cortex | 0.074 [0.067, 0.077] (0.060, 0.086) | 0.074 [0.070, 0.076] (0.034, 0.078) | 0.826 |
Thalamus | 0.011 [0.010, 0.011] (0.008, 0.012) | 0.010 [0.010, 0.011] (0.010, 0.014) | 0.889 |
Temporal cortex | 0.063 [0.061, 0.067] (0.050, 0.076) | 0.063 [0.061, 0.065] (0.021, 0.072) | 0.826 |
Cingulate cortex | 0.013 [0.012, 0.014] (0.011, 0.015) | 0.013 [0.013, 0.014] (0.003, 0.015) | 0.704 |